CT-guided iodine-125 seed permanent implantation for recurrent head and neck cancers

Abstract

Background To investigate the feasibility, and safety of 125 I seed permanent implantation for recurrent head and neck carcinoma under CT-guidance. Results A retrospective study on 14 patients with recurrent head and neck cancers undergone 125 I seed implantation with different seed activities. The post-plan showed that the actuarial D90 of 125 I seeds ranged from 90 to 218 Gy (median, 157.5 Gy). The follow-up was 3 to 60 months (median, 13 months). The median local control was 18 months (95% CI, 6.1-29.9 months), and the 1-, 2-, 3-, and 5- year local controls were 52%, 39%, 39%, and 39%, respectively. The 1-, 2-, 3-, and 5- survival rates were 65%, 39%, 39% and 39%, respectively, with a median survival time of 20 months (95% CI, 8.7-31.3 months). Of all patients, 28.6% (4/14) died of local recurrence, 7.1% (1/14) died of metastases, one patient died of hepatocirrhosis, and 8 patients are still alive to the date of data analysis. Conclusion CT-guided 125 I seed implantation is feasible and safe as a salvage or palliative treatment for patients with recurrent head and neck cancers.

Surgery combined with postoperative 125I seed brachytherapy for the treatment of mucoepidermoid carcinoma of the parotid gland in pediatric patients

“…Postoperative 125 I seed brachytherapy delivers a high dose of radiation directly to the tumor, minimizing nontarget dose dispersal to the adjacent normal structures, and is increasingly being found effective for treating patients with malignant head and neck tumors and improving local control (LC) and patient survival. 12,13 In adult patients with parotid gland malignances, 125 I seed brachytherapy has been proved effective with minor radiation-associated side effects. [14][15][16][17] To determine the long-term outcomes and associated complications among pediatric patients with MEC of the parotid gland treated with a combination of surgery and postoperative 125 I seed brachytherapy, we retrospectively reviewed patient data from Peking University School and Hospital of Stomatology.…”

Postoperative 125I brachytherapy delivered by digital model obturators for recurrent or locally advanced maxillary cancers

“…Other radioactive seeds were interstitially implanted into soft tissue with the patient under local or general anesthesia by intra‐ or extra‐oral puncture with implantation needles under CT guidance (Fig. 2B) 21. After interstitial implantation, the digital model obturator containing 125 I radioactive seeds was inserted.…”

“…Brachytherapy can deliver a high radiation dose to a tumor while sparing surrounding normal vital tissues 20, 21. The low dose rate of 125 I irradiation can enhance the tolerance of normal tissues 22.…”

“…The low dose rate of 125 I irradiation can enhance the tolerance of normal tissues 22. Several reports have analyzed the benefits of 125 I brachytherapy used alone or combined with surgery for head and neck cancers 21–25…”

Control Strategy and Experiments for Robot Assisted Craniomaxillofacial Surgery System

“…Needle puncture accuracy affects surgical treatment effect and may cause harm to the patient. Although technical assistance methods have been provided for needle puncture surgery, including conventional CT guide [6], individual template assistance, and image navigation [7], accurate needle placement still depends largely to a great extent on the surgeon's experience and hand-eye-mind coordination.…”